AmpliMed Corporation to Present Clinical Data from Three Clinical Trials of Amplimexon at American Society of Clinical Oncology Annual MeetingTUCSON, Ariz.--(BUSINESS WIRE)--May 30, 2008 - AmpliMed Corporation, a cancer therapeutics company, today announced that data from three clinical trials of Amplimexon(R) in various cancer types will be presented during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 30 to June 3, 2008, at McCormick Place in Chicago. Investigators will present final results from a Phase 1/2 trial of Amplimexon (imexon for injection) in metastatic melanoma, updated data from a Phase 1 trial of Amplimexon in combination with docetaxel (Taxotere) in breast, lung and prostate cancer and updated data from a Phase 1 trial of Amplimexon in combination with gemcitabine (Gemzar(R)) in advanced pancreatic cancer.
Amplimexon, AmpliMed's lead product candidate, is a chemotherapeutic that has demonstrated clinical and preclinical activity against a range of tumors. It has been evaluated in nearly 300 patients and has demonstrated clinical activity both as a monotherapy and in combination with other therapies.
"These presentations at ASCO highlight the applicability of Amplimexon for a wide range of cancer types," said Robert T. Dorr, Ph.D. R. Ph., Chief Executive Officer of AmpliMed.
Poster Presentation Details
"A Phase I/II Study of Imexon (AMP) Plus Dacarbzine (DTIC) in patients with Metastatic Malignant Melanoma"
Authors: W.E. Samlowski, J.S. Weber, R. Gonzalez, A. Ribas, S.J. O'Day, J.J. Stephenson, T. Sato, R.T. Dorr, K.A. Grenier, E.M. Hersh
General Poster Session: Saturday, May 31, 2 p.m. to 6 p.m.
"A Phase I Study of Imexon in Combination with Docetaxel (DOC) for the Treatment of Patients with Breast, Lung and Prostate Cancer"
Authors: S.L. Moulder, N. Dhillon, D.S. Hong, C.S. Ng, L.H. Camacho, E.M. Hersh, K.A. Grenier, M.L. Boytim, R.T. Dorr, R. Kurzrock
General Poster Session: Sunday, June 1, 2 p.m. to 6 p.m.
"A Phase I Study of Imexon Inj. Plus Gemcitabine as First-line Therapy for Advanced Pancreatic Cancer with Preclinical Mechanistic Study of Dose Limiting Toxicity"
Authors: S.J. Cohen, M.M. Zalupski, M.R. Modiano, P.R. Conkling, Y.Z. Patt, P. Davis, R.T. Dorr, M.L. Boytim, E.M. Hersh
General Poster Session: Sunday, June 2, 8 a.m. to noon.
Amplimexon is a small molecule drug that increases oxidative stress in tumor cells, leading to mitochondrial damage and apoptosis (cell death). Preclinical studies show that combined use of Amplimexon and certain other chemotherapeutics resulted in a significant increase in efficacy compared to either drug alone. Amplimexon appears to suppress the activity of bone marrow only at the highest doses and may thus avoid some of the toxic side effects that limit the use of other chemotherapeutics.
About AmpliMed Corporation
AmpliMed Corporation is a privately held company focused on the clinical development of chemotherapeutic agents for cancer. AmpliMed's strategy is to develop anti-cancer drugs with novel mechanisms of action designed to overcome some of the limitations, such as myelosuppression, multi-drug resistance and cardiac toxicity, frequently associated with current cancer therapies. The company's lead product, Amplimexon, is in Phase II clinical trials. For more information about AmpliMed, please visit www.amplimed.com.
Note that the data represented in this press release is provided as a snapshot of unaudited data, and thus final results may be marginally different after all auditing activities are concluded.
AmpliMed, Amplimexon and Amplizone are United States trademarks of AmpliMed Corporation.
Julie Rathbun, 206-769-9219
Posted: May 2008